RxDoctor Payments Data

Mitchell Devlin, DO

Interventional Cardiology · Spartanburg, SCNPI 1700888468

Payments from drug & device makers

$2,821in general payments, 2019–2025

Across 93 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$766
  • Abiomed$462
  • Stryker$379
  • Abbott$275
  • Edwards Lifesciences$175
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$114
  • plus $651 from 17 others

What the payments were for

  • Food & beverage$2,821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,821 in reported general payments places this provider in the 10th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$46,600
Medicare patients
258
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$108,407
EntrestoSacubitril/Valsartan34$34,272
XareltoRivaroxaban17$14,994
BrilintaTicagrelor15$10,895
Metoprolol Succinate137$1,644
Atorvastatin Calcium58$805
Rosuvastatin Calcium32$786
Labetalol Hcl12$696
SotalolSotalol Hcl14$582
ClopidogrelClopidogrel Bisulfate59$538
Valsartan27$512
Losartan Potassium41$491
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$478
Spironolactone55$437
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$108,407125 claims
NovartisEntresto$19$34,27234 claims
Johnson & JohnsonXarelto$39$14,99417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →